Electromed, Inc. Form 10-Q Summary
Reporting period: Fiscal second quarter and six months ended December 31, 2022. The filing was signed February 14, 2023. Electromed develops, manufactures and markets SmartVest airway-clearance systems using High Frequency Chest Wall Oscillation technology for home-care, institutional and international markets.
Financial Results and Position
| Metric | Three months ended Dec. 31, 2022 | Three months ended Dec. 31, 2021 | Six months ended Dec. 31, 2022 | Six months ended Dec. 31, 2021 |
|---|---|---|---|---|
| Net revenue | $11.729 million | $10.248 million | $22.387 million | $20.249 million |
| Gross profit | $8.682 million | $7.880 million | $17.013 million | $15.581 million |
| Gross margin | 74.0% | 76.9% | 76.0% | 76.9% |
| Operating income | $1.274 million | $1.076 million | $1.318 million | $1.614 million |
| Net income | $977,000 | $838,000 | $1.058 million | $1.277 million |
| Diluted EPS | $0.11 | $0.10 | $0.12 | $0.15 |
- Second-quarter operating margin was approximately 10.9%, compared with 10.5% in the prior-year quarter. Six-month operating margin was approximately 5.9%, compared with 8.0%.
- SG&A increased 12.0% in the quarter and 14.9% year to date, primarily from higher sales, sales-support, marketing and reimbursement staffing costs. R&D declined 53.5% in the quarter and 35.9% year to date as Clearway development-related professional services decreased.
- At December 31, 2022, cash and cash equivalents were $6.909 million, compared with $8.153 million at June 30, 2022. Working capital was $28.153 million.
- Total assets were $41.394 million and total liabilities were $6.044 million at December 31, 2022. Shareholders’ equity was $35.350 million.
- Accounts receivable were $21.555 million, contract assets were $507,000 and inventories were $3.473 million at period end.
- Net cash used in operating activities was $330,000 for the six months ended December 31, 2022, compared with $106,000 used in the prior-year period. Investing cash use was $717,000, principally for enterprise resource planning infrastructure, property and equipment and intangible assets. Financing cash use was $197,000, including $153,000 of share repurchases.
- There was no outstanding debt under the $2.5 million revolving credit facility. The full $2.5 million was available at December 31, 2022. The facility expires December 18, 2023, if not renewed, and is subject to financial and nonfinancial covenants.
Material Changes Versus the Prior Comparable Period
- Total revenue increased 14.5% in the quarter and 10.6% for the six-month period. Home-care revenue increased 14.1% and 9.0%, respectively, primarily from higher referrals and approvals.
- Institutional revenue increased 76.9% in the quarter and 25.3% year to date, primarily due to higher capital sales.
- Home-care distributor revenue decreased 13.2% in the quarter but increased 63.9% year to date, reflecting the timing of purchases by a major distribution partner.
- International revenue declined 41.9% in the quarter and 35.2% year to date.
- Gross margin declined 290 basis points in the quarter and 90 basis points year to date because of higher material costs and expedited shipping expenses.
- Quarterly net income increased 16.6%, while six-month net income decreased 17.2%. Year-to-date earnings were pressured by investments in sales and reimbursement capacity despite higher gross profit.
- Cash declined $1.244 million during the six months, compared with a $1.419 million decline in the prior-year period. The company repurchased 15,368 shares for $153,000 during the period and had repurchased and retired 239,995 shares for $2.725 million in total under its authorization as of December 31, 2022.
Guidance, Outlook, Risks and Unusual Items
- Electromed received FDA 510(k) clearance for the next-generation SmartVest Clearway system in December 2022, began a limited market release and expected a full launch in fiscal third quarter 2023.
- Management stated that cash, operating cash flows and available credit should provide adequate liquidity for fiscal 2023 and the foreseeable future. No formal revenue or earnings guidance was provided in the filing.
- The CMS COVID-19 waiver for certain Medicare respiratory-device documentation requirements was extended beginning January 11, 2023. Management expected the waiver to terminate no later than the May 11, 2023 public-health-emergency end date, potentially causing approval delays, cancellations or appeals and a one-time delay in some Medicare revenue.
- Supply-chain disruptions from September through December 2022 caused temporary product-availability interruptions. Management expects elevated component lead times, material costs and shipping rates to potentially continue through the second half of fiscal 2023.
- Key risks include reimbursement changes, expiration of the CMS waiver, supply shortages, inflation, Clearway launch execution, regulatory compliance and approvals, competition, sales-force expansion, cybersecurity and data breaches, and renewal of the credit facility.
- The company faces a putative class action related to a prior data breach. A settlement was preliminarily approved in January 2023, with final approval scheduled for June 5, 2023. The filing states that the ultimate outcome and potential loss exposure cannot currently be determined.
- The warranty reserve increased to $1.337 million from $1.256 million at June 30, 2022. The company provides a lifetime warranty for U.S. patient sales and a three-year warranty for institutional and non-U.S. individual sales.
- Critical estimates include revenue recognition and variable consideration, inventory valuation, share-based compensation and warranty reserves. Interim results are not necessarily indicative of full-year results.
Investor Verification Checklist
- Verify the timing and commercial performance of the Clearway full launch, including regulatory, manufacturing and adoption milestones.
- Assess the effect of CMS waiver expiration on Medicare referrals, approval times, cancellations and revenue recognition.
- Track gross-margin performance against continued material-cost, freight and supply-chain pressures.
- Evaluate whether sales-force and reimbursement investments convert into sustainable revenue and operating-cash-flow growth.
- Monitor cash conversion, accounts receivable, contract assets and inventory levels given the six-month operating cash outflow.
- Confirm renewal or replacement of the $2.5 million credit facility before its December 18, 2023 expiration.
- Review final court approval and any financial or operational consequences of the data-breach settlement.